Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome

Trial Profile

A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teduglutide (Primary)
  • Indications Short bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms STEPS
  • Sponsors NPS Pharmaceuticals
  • Most Recent Events

    • 01 Jun 2022 According to a Takeda media release, the National Institute for Health and Care Excellence (NICE), has published its Final Appraisal Document (FAD) recommending Revestive (teduglutide) once daily subcutaneous injection as an option for people living with Short Bowel Syndrome (SBS) aged 1 year and above. Key evidence behind the NICE recommendation was data from the STEPS and STEPS-2 trials.
    • 15 Nov 2021 Results of Post- Hoc analysis from NCT00081458 and NCT00798967, evaluating patient liver chemistries, presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases
    • 22 Jan 2018 According to a Shire media release, post-hoc analyses data will be presented at the ASPEN 2018 Nutrition Science & Practice.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top